US2007129561A1PendingUtilityA1

Method for the separation of intermediates which may be used for the preparation of escitalopram

36
Assignee: TAOKA NAOKIPriority: Aug 12, 2002Filed: Aug 12, 2003Published: Jun 7, 2007
Est. expiryAug 12, 2022(expired)· nominal 20-yr term from priority
C07C 253/34C12P 13/002C12P 7/22C07C 255/59C07C 253/30C12P 41/007C12P 13/008C12P 13/001C12P 13/02C07B 57/00C07D 307/87C07B 2200/07C07C 255/34C07C 255/53
36
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a novel method for the preparation of diol intermediates having the formula (II) and/or the opposite enantiomer of an acylated diol having the formula (IV) useful for the preparation of escitalopram involving selective enzymatic acylation or deacylation.

Claims

exact text as granted — not AI-modified
1 . A method for the preparation of the S- or R-enantiomer of a diol having the formula  
     
       
         
         
             
             
         
       
     
     or a salt thereof; 
 wherein R is cyano or a group which may be converted to a cyano group, Z is —CH 2 —N(R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, the dotted line is a double or single bond and Hal is a halogen; and/or  
 the opposite enantiomer of an acylated diol having the formula  
                     
 or a salt thereof;  
 wherein R, Z, the dotted line and Hal are as defined above, W is O or S, and R 3  is —Y—R 1  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein any of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH, comprising  
 a) subjecting a racemic compound of formula  
                     wherein R, Z, the dotted line and Hal are as defined above, to selective enzymatic acylation using an acylating agent having the formula                           or an isocyanate having the formula R 1 —N═C═O or an isothiocyanate having the formula R 1 —N═C═S;    wherein X is O or S; W is O or S; U is O or S; and V is halogen;    R 0  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 0  is aryl, wherein any of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;    R 1  is as defined above for R 0 ;    R 2  is as defined above for R 0 , or R 2  is a suitable leaving group;    or R 0  and R 1  together form a chain of 3 to 5 carbon atoms;    provided that W and U are not S when X is S; to form a mixture of the starting material of formula (II) in either the R- or the S-form and opposite enantiomer of a compound having the formula                          wherein R, W, Hal, R 3 , the dotted line and Z are as defined above; or    
 b) subjecting a racemic compound of formula  
                     wherein R, Z, W, Hal, the dotted line and R 3  are as defined above; to selective enzymatic deacylation to form a mixture of deacylated compound of formula                          wherein R, Hal, the dotted line and Z are as defined above in either the R- or the S-form and the acylated starting material of formula (IV) in the form of the opposite enantiomer; and    
 c) optionally isolating, in either order, the S- or R-enantiomer of the compound of formula (II) or a salt thereof and/or the opposite enantiomer of the compound of formula (IV) or a salt thereof.  
 
   
   
       2 . The method of  claim 1 , comprising step a).  
   
   
       3 . The method of  claim 1 , comprising step b).  
   
   
       4 . The method of  claim 2  wherein the acylation of the compound of formula (II) results in a mixture containing the compound of formula (II) in the S-form and the compound of formula (IV) in the R-form.  
   
   
       5 . The method of  claim 2  wherein the acylation of the compound of formula (II) results in a mixture containing the compound of formula (II) in the R-form and the compound of formula (IV) in the S-form.  
   
   
       6 . The method of  claim 3  wherein the deacylation of the compound of formula (IV) results in a mixture containing the compound of formula (IV) in the S-form and the compound of formula (II) in the R-form.  
   
   
       7 . The method of  claim 3  wherein the deacylation of the compound of formula (IV) results in a mixture containing the compound of formula (IV) in the R-form and the compound of formula (II) in the S-form.  
   
   
       8 . The method of  claim 1  wherein Hal is fluoro and R is halogen or cyano.  
   
   
       9 . The method of  claim 1  wherein the dotted line represents a single bond.  
   
   
       10 . The method of  claim 1  wherein Z is dimethylarninomethyl.  
   
   
       11 . (canceled)  
   
   
       12 . (canceled)  
   
   
       13 . The method of  claim 2  wherein the acylating agent is a compound of formula (IIIa).  
   
   
       14 . The method of  claim 2  wherein the acylating agent is a compound of formula (IIIb).  
   
   
       15 . The method of  claim 2  wherein the acylating agent is a compound of formula (IIIc).  
   
   
       16 . The method of  claim 2  wherein U is O.  
   
   
       17 . The method of  claim 2  wherein W is O.  
   
   
       18 . The method of  claim 2  wherein X is O.  
   
   
       19 . The method of  claim 2  wherein 
 R 0 , and R 1  are each independently selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino, or R 0  and R 1  together form a chain of 3-5 carbon atoms; and    R 2  is selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino, or R 2  is a leaving group.    
   
   
       20 . The method of  claim 19  wherein R 0 , R 1  and R 2  are each independently selected from C 1-3 -alkyl, C 2-3 -alkenyl and C 2-3 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-3 -alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino.  
   
   
       21 . The method of  claim 20  wherein R 0  and R 1  are each independently C 1-3 -alkyl, and R 2  is C 1-3 -alkyl substituted one or more times with halogen, or R 2  is C 2-3 -alkenyl.  
   
   
       22 . The method of  claim 13  wherein R 0  and R 1  are each independently selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino.  
   
   
       23 . The method of  claim 22  wherein R 0  and R 1  are each independently selected from C 1-3 -alkyl, C 2-3 -alkenyl or C 2-3 -alkynyl, all of which may all optionally be substituted one or more times with substituents selected from C 1-3 -alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino.  
   
   
       24 . The method of  claim 22  wherein R 0  and R 1  are each independently C 1-4 -alkyl.  
   
   
       25 . The method of  claim 24  wherein R 0  and R 1  are each independently C 1-3 -alkyl.  
   
   
       26 . The method of  claim 14  wherein 
 R 1  is selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-6 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino; and    R 2  is selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-6 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino, or R 2  is a leaving group.    
   
   
       27 . The method of  claim 26  wherein R 1  is selected from C 1-3 -alkyl, C 2-3 -alkenyl and C 2-3 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-3 -alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino and R 2  is C 1-4 -alkyl substituted one or more times with halogen, or R 2  is C 2-4 -alkenyl.  
   
   
       28 . The method of  claim 27  wherein R 2  is C 1-3 -alkyl substituted one or more times with halogens or R 2  is C 2-3 -alkenyl.  
   
   
       29 . The method of  claim 27  wherein R 1  is C 1-3 -alkyl.  
   
   
       30 . The method of  claim 29  wherein R 1  is selected from methyl, ethyl, propyl, and C 1-3 -alkyl substituted one or more times with halogen; and R 2  is C 2-3 -alkenyl.  
   
   
       31 . The method of  claim 30  wherein R 2  is vinyl.  
   
   
       32 . The method of  claim 31  wherein R 1  is propyl.  
   
   
       33 . The method of  claim 15  wherein R 1  is selected from C 1-4 -alkyl, C 2-4 -alkenyl and C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl)amino.  
   
   
       34 . The method of  claim 33  wherein R 1  is selected from C 1-3 -alkyl, C 2-3 -alkenyl and C 2-3 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-3 -alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino.  
   
   
       35 . The method of  claim 34  wherein R 1  is C 1-3 -alkyl, C 2-3 -alkenyl or C 2-3 -alkynyl.  
   
   
       36 . The method of  claim 2  wherein the acylating agent is an isocyanate of formula R 1 —N═C═O or an isothiocyanate of the formula R 1 —N═C═S.  
   
   
       37 . The method of  claim 36  wherein the acylating agent is an isothiocyanate of the formula R 1 —N═C═S.  
   
   
       38 . The method of  claim 36  wherein the acylating reagent is an isocyanate of formula R 1 —N═C═O.  
   
   
       39 . The method according to of  claim 36  wherein R 1  is C 1-4 -alkyl, C 2-4 -alkenyl or C 2-4 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-4 -alkylamino and di-(C 1-4 -alkyl) amino.  
   
   
       40 . The method of  claim 39  wherein R 1  is C 1-3 -alkyl, C 2-3 -alkenyl or C 2-3 -alkynyl, all of which may optionally be substituted one or more times with C1-3-alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino.  
   
   
       41 . The method of  claim 40  wherein R 1  is C 1-3 -alkyl, C 2-3 -alkenyl or C 2-3 -alkynyl.  
   
   
       42 . The method of  claim 40  wherein R 1  is methyl, ethyl, or propyl.  
   
   
       43 . The method of  claim 1  wherein Y is O or S.  
   
   
       44 . The method of  claim 43  wherein Y is O.  
   
   
       45 . The method of  claim 43  wherein Y is S.  
   
   
       46 . The method of  claim 3  wherein Y is a bond.  
   
   
       47 . The method of  claim 3  wherein Y is NH.  
   
   
       48 . The method of  claim 3  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino.  
   
   
       49 . The method of  claim 48  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl all of which may optionally be substituted one or more times with substituents selected from hydroxy, halogen, amino, nitro and cyano.  
   
   
       50 . The method of  claim 49  wherein R 1  is C 1-10 -alkyl.  
   
   
       51 . The method of  claim 1  wherein the enzymatic acylation of step a) or the enzymatic deacylation of step b) is performed with a hydrolase enzyme.  
   
   
       52 . The method of  claim 51  wherein the hydrolase enzyme is selected from a lipase, an esterase, an acylase, and a protease.  
   
   
       53 . The method of  claim 51  wherein the hydrolase enzyme is in the form of an immobilized enzyme or a Cross-Linked Enzyme Crystal enzyme.  
   
   
       54 . The method of  claim 51  wherein the hydrolase enzyme used is selected from  Pseudomonas  sp. lipoprotein lipase,  Candida antartica  lipase B,  Thermomyces lanuginosus  lipase, and mutants and variants thereof.  
   
   
       55 . The method of  claim 54  wherein the hydrolase enzyme is selected from  Pseudomonas  sp. lipoprotein lipase, and mutants and variants thereof.  
   
   
       56 . The method of  claim 55  wherein the hydrolase enzyme is  Pseudomonas  sp. lipoprotein lipase.  
   
   
       57 . The method of  claim 54  wherein the hydrolase enzyme is selected from  Candida antartica  lipase B, and mutants and variants thereof.  
   
   
       58 . The method of  claim 57  wherein the hydrolase enzyme is  Candida antartica  lipase B.  
   
   
       59 . The method of  claim 58  wherein the hydrolase enzyme is  Candida antaitica  lipase B immobilized on acrylic resin.  
   
   
       60 . The method of  claim 54  wherein the hydrolase enzyme is selected from  Thermomyces lanuginosus  lipase, and mutants and variants thereof.  
   
   
       61 . The method of  claim 60  wherein the hydrolase enzyme is  Thermomyces lanuginosus  lipase.  
   
   
       62 . The method of  claim 61  wherein the hydrolase enzyme is an immobilized 1,3-regioselective lipase.  
   
   
       63 . The method of  claim 1  wherein the enzymatic acylation or the enzymatic deacylation is carried out in presence of an organic base, an organic acid or a mixture thereof.  
   
   
       64 . The method of  claim 63  wherein the enzymatic acylation or enzymatic deacylation is carried out in the presence of an organic acid.  
   
   
       65 . The method of  claim 64  wherein the enzymatic acylation is carried out in the presence of an organic acid.  
   
   
       66 . The method of  claim 64  wherein the organic acid is an aromatic carboxylic acid or an aliphatic carboxylic acid.  
   
   
       67 . The method of  claim 64  wherein the organic acid is selected from n-propionic acid, iso-propionic acid, n-butyric acid, iso-butyric acid, iso-valeric acid, 2-ethylbutyric acid, cyclohexanecarboxylic acid, pivalic acid, benzoic acid, p-toluic acid, salicylic acid and 3-phenylpropionic acid.  
   
   
       68 . The method of  claim 67  wherein the organic acid is pivalic acid.  
   
   
       69 . The S- or R-enantiomer of a compound having the formula (IV)  
     
       
         
         
             
             
         
       
     
     or a salt thereof; 
 wherein R is cyano or a group which may be converted to cyano, Z is —CH 2 —N(R′R″) wherein R′ and R″ are each independently C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, Hal is a halogen, W is O or S, the dotted line represents a double or a single bond, R 3  is —Y—R 1 , wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino and Y is a bond, O, S or NH.  
 
   
   
       70 . The enantiomer of  claim 69  wherein Hal is fluoro, and R is halogen or cyano.  
   
   
       71 . The enantiomer of  claim 69  wherein the dotted line represents a single bond.  
   
   
       72 . The enantiomer of  claim 70  wherein Z is dimethylaminomethyl.  
   
   
       73 . The enantiomer of  claim 69  wherein Y is O or S.  
   
   
       74 . The enantiomer of  claim 73  wherein Y is O.  
   
   
       75 . The enantiomer of  claim 73  wherein Y is S.  
   
   
       76 . The enantiomer of  claim 69  wherein Y is a bond.  
   
   
       77 . The enantiomer of  claim 69  wherein Y is NH.  
   
   
       78 . The enantiomer of  claim 69  wherein R 1  is C 1-4 -alkyl, C 2-4 -alkenyl or C 2-4 -alkynyl, all of which may optionally be substituted and or more times with substituents selected from C 1-4 -alkoxy, C 1-4 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-6 -alkylamino and di-(C 1-4 -alkyl) amino.  
   
   
       79 . The enantiomer of  claim 78  wherein R 1  is C 1-3 -alkyl, C 2-3 -alkenyl or C 2-3 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-3 -alkoxy, C 1-3 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-3 -alkylamino and di-(C 1-3 -alkyl) amino.  
   
   
       80 . The enantiomer of  claim 79  wherein R 1  is C 1-3 -alkyl.  
   
   
       81 . The enantiomer of  claim 69  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-6 -alkylamino and di-(C 1-10 -alkyl) amino.  
   
   
       82 . The enantiomer of  claim 81  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from hydroxy, halogen, amino, nitro and cyano.  
   
   
       83 . The enantiomer of  claim 82  wherein R 1  is C 1-10 -alkyl.  
   
   
       84 . A method for the isolation and purification of the S- or R-enantiomer of a compound the of formula (IV)  
     
       
         
         
             
             
         
       
     
     or a salt thereof; 
 wherein R is cyano or a group which may be converted to a cyano group, the dotted line represents a double or single bond, Hal is a halogen, Z is —CH 2 —N (R″R″) wherein R′ R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, W is O or S, and R 3  is —Y—R 1  wherein Y is a bond, O, S or NH 1  and R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted with one or more substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;  
 and/or the opposite enantiomer of a diol of formula (II)  
                     
 or a salt thereof;  
 wherein R, Z, Hal and the dotted line are as defined above, from a mixture containing the S- or R-enantiomer of the compound of formula (IV) and the opposite enantiomer of the diol of formula (II), comprising:  
 a) treating the mixture with an acid in a mixture of water and an organic solvent;  
 b) separating the aqueous phase containing the diol of formula (II) as a salt of said acid from the organic phase to obtain an organic phase containing the compound of formula (IV) as a salt of said acid;  
 c) optionally isolating the diol of formula (II) as the base or a salt thereof; and  
 d) optionally isolating of the compound of formula (IV) as the base or a salt thereof.  
 
   
   
       85 . The method of  claim 84  wherein the S-enantiomer of the diol of formula (II) is separated from the R-enantiomer of the compound of formula (IV).  
   
   
       86 . The method of  claim 84  wherein the S-enantiomer of the compound of formula (IV) is separated from the R-enantiomer of the diol of formula (II).  
   
   
       87 . The method of  claim 84  wherein the mixture of step a) is prepared by a method comprising 
 a) subjecting a racemic diol of formula (II)                          wherein R is cyano or a group which may be converted to a cyano group, Z is —CH 2 —N(R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, the dotted line is a double or single bond, and Hal is a halogen;    to selective enzymatic acylation using an acylating agent having the formula                          or an isocyanate having the formula R 1 —N═C═O or an isothiocyanate having the formula R 1 —N═C═S; wherein X is O or S; W is O or S; U is O or S; and V is halogen; provided that each of W and U is not S when X is S;    R 0  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 0  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;    R 1  is as defined above for R 0 ; or R 0  and R 1  together form a chain of 3 to 5 carbon atoms;    R 2  is as defined above for R 0 , or R 2  is a suitable leaving group;    to form a mixture of the S- or R-enantiomer of a diol of formula (II) and the opposite enantiomer of a compound of formula (IV)                          wherein R, Hal, the dotted line and Z are as defined above;    wherein W is O or S, and R3 is —Y—R 1  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH; or    b) subjecting a racemic compound of formula (IV)                          wherein R, Z, W, Hal, the dotted line and R 3  are as defined above; to selective enzymatic deacylation to form a mixture of the S- or R-enantiomer of a diol of formula (II)                          wherein R, Hal, the dotted line and Z are as defined above, and the opposite enantiomer of a compound of formula (IV).    
   
   
       88 . A method for isolation and purification of the S- or R-enantiomer of an acyl derivative of formula (IV)  
     
       
         
         
             
             
         
       
     
     or a salt thereof; 
 wherein R is cyano or a group which may be converted to a cyano group, Hal is a halogen, the dotted line represents a double or a single bond, Z is —CH 2 —N (R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, W is O or S; and R 3  is —Y—R 1  wherein Y is a bond, O, S or NH; and R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -Alkylamino and di-(C 1-10 -alkyl) amino and/or the opposite enantiomer of a diol of formula (II)  
                     
 or a salt thereof;  
 wherein R, Hal, Z and the dotted line are as defined above, from a mixture containing the S- or R-enantiomer of the acyl derivative of formula (IV) and the opposite enantiomer of the diol of formula (II), comprising:  
 a) treating the mixture with a mixture of water, a protic organic solvent and an apolar organic solvent;  
 b) separating the aqueous phase containing the diol of formula (II) from the organic phase to obtain an organic phase containing the acyl derivative of formula (IV);  
 c) optionally isolating the diol of formula (II) from the aqueous phase and/or the acyl derivative of formula (IV) from the organic phase, and  
 d) optionally converting the diol of formula (II) and/or the compound of formula (IV) to a salt thereof.  
 
   
   
       89 . The method of  claim 88  wherein the S-enantiomer of the diol of formula (II) is separated from the R-enantiomer of the acyl derivative of formula (IV).  
   
   
       90 . The method of  claim 88  wherein the S-enantiomer of the acyl derivative of formula (IV) is separated from the R-enantiomer of the diol of formula (II).  
   
   
       91 . The method of  claim 88  wherein the mixture of step a) is prepared by a method comprising 
 a) subjecting a racemic diol of formula (II)                          wherein R is cyano or a group which may be converted to a cyano group, Z is —CH 2 —N(R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, the dotted line is a double or single bond, and Hal is a halogen;    to selective enzymatic acylation using an acylating agent having the formula                          or an isocyanate having the formula R 1 —N═C═O or an isothiocyanate having the formula R′—N═C═S; wherein X is O or S; W is O or S; U is O or S; and V is halogen; provided that each of W and U is not S when X is S;    R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 0  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;    R 1  is as defined above for R 0 ; or R′ and R 1  together form a chain of 3 to 5 carbon atoms;    R 2  is as defined above for R 0 , or R 2  is a suitable leaving group;    to form a mixture of the S- or R-enantiomer of a diol of formula (II) and the opposite enantiomer of a compound of formula (IV)                          wherein R, Hal, the dotted line and Z are as defined above;    wherein W is O or S, and R3 is —Y—R 1  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH; or    b) subjecting a racemic compound of formula (IV)                          wherein R, Z, W, Hal, the dotted line and R 3  are as defined above; to selective enzymatic deacylation to form a mixture of the S- or R-enantiomer of a diol of formula (II)                          wherein R, Hal, the dotted line and Z are as defined above, and the opposite enantiomer of a compound of formula (IV).    
   
   
       92 . A process for the preparation of escitalopram having the formula  
     
       
         
         
             
             
         
       
       or a pharmaceutically acceptable salt thereof, comprising  
       (i) preparing the S-enantiomer of a diol having the formula (IIs)  
       
         
           
           
               
               
           
         
       
       or a salt thereof;  
       wherein R is cyano or a group which may be converted to a cyano group, the dotted line represents a double or a single bond, Z is a dimethylaminomethyl group or a group which may be converted to a dimethylaminomethyl group and Hal is a halogen, or  
       (ii) preparing the S-enantiomer of an acylated diol having the formula (IVs)  
       
         
           
           
               
               
           
         
       
       or a salt thereof;  
       wherein R, Z, the dotted line and Hal are as defined above, W is O or S, and R 3  is —Y—R 1 , wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH, wherein the diol of formula (IIs) and/or the acylated diol of formula (IVs) is prepared by a method comprising:  
       (a) subjecting a racemic diol of formula (II)  
       
         
           
           
               
               
           
         
       
       wherein R is cyano or a group which may be converted to a cyano group, Z is —CH 2 —N(R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, the dotted line is a double or single bond, and Hal is a halogen;  
       to selective enzymatic acylation using an acylating agent having the formula  
       
         
           
           
               
               
           
         
       
       or an isocyanate having the formula R 1 —N═C═O or an isothiocyanate having the formula R 1 —N═C═S; wherein X is O or S; W is O or S; U is O or S; and V is halogen; provided that each of W and U is not S when X is S;  
       R 0  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 0  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;  
       R 1  is as defined above for R 0 ; or R 0  and R 1  together form a chain of 3 to 5 carbon atoms;  
       R 2  is as defined above for R 0 , or R 2  is a suitable leaving group;  
       to form a mixture of the S- or R-enantiomer of a diol of formula (II) and the opposite enantiomer of a compound of formula (IV)  
       
         
           
           
               
               
           
         
       
       wherein R, Hal, the dotted line and Z are as defined above;  
       wherein W is O or S, and R 3  is —Y—R 1  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH; or  
       (b) subjecting a racemic compound of formula (IV)  
       
         
           
           
               
               
           
         
       
       wherein R, Z, W, Hal, the dotted line and R 3  are as defined above; to selective enzymatic deacylation to form a mixture of the S- or R-enantiomer of a diol of formula (II)  
       
         
           
           
               
               
           
         
       
       wherein R, Hal, the dotted line and Z are as defined above, and the opposite enantiomer of a compound of formula (IV); and  
       (c) isolating, in either order, the S- or R-enantiomer of the compound of formula (II) or a salt thereof and/or the opposite enantiomer of the compound of formula (IV) or a salt thereof;  
       (iii) optionally subjecting the diol of formula (IIs) or the acylated diol of formula (IVs) to one or more reactions, in any order, selected from,  
       (a) conversion of the group R to a cyano group,  
       (b) conversion of the group Z to a dimethylaminomethyl group,  
       (c) reduction of a double bond represented by the dotted line to a single bond and/or  
       (d) conversion of the group Hal to a fluoro group;  
       (iv) effecting ring closure under basic conditions of the diol of formula (IIs) or the acylated diol of formula (IVs), or a labile ester derivative thereof, to form a compound of formula (V)  
       
         
           
           
               
               
           
         
       
       (v) subjecting the compound of formula (V) to, in any order:  
       (a) conversion of the group R to a cyano group, if R is not cyano,  
       (b) conversion of the group Z to a dimethylaminomethyl group, if Z is not dimethylaminomethyl,  
       (c) reduction to a single bond, if the dotted line represents a double bond, and  
       (d) conversion of Hal to a fluoro group, if Hal is not fluoro; and  
       (vi) isolating escitalopram or a pharmaceutically acceptable salt thereof.  
     
   
   
       93 . The method of  claim 92  wherein the R- or S-enantiomer of a the diol of formula (II) and the opposite enantiomer of the compound of formula (IV) are separated from each other by a process comprising 
 (a) treating the mixture with an acid in a mixture of water and an organic solvent;    (b) separating the aqueous phase containing the diol of formula (II) as a salt of said acid from the organic phase to obtain an organic phase containing the compound of formula (IV) as a salt of said acid;    (c) optionally isolating the diol of formula (II) as the base or a salt thereof; and    (d) optionally isolating the compound of formula (IV) as the base or a salt thereof.    
   
   
       94 . The method of  claim 92  wherein the R- or S-enantiomer of a the diol of formula (II) and the opposite enantiomer of the compound of formula (IV) are separated from each other by a process comprising 
 a) treating the mixture with a mixture of water, a protic organic solvent and an apolar organic solvent;    b) separating the aqueous phase containing the diol of formula (II), from the organic phase to obtain an organic phase containing the compound of formula (IV);    c) optionally isolating the diol of formula (II) from the aqueous phase and/or the compound of formula (IV) from the organic phase; and    d) optionally converting the diol of formula (II) and/or the compound of formula (IV) to a salt thereof.    
   
   
       95 . A method for the preparation of racemic citalopram and/or escitalopram or a pharmaceutically acceptable salt thereof comprising  
     (i) preparing the R-enantiomer of a diol having the formula (IIr)  
     
       
         
         
             
             
         
       
       or a salt thereof;  
       wherein R is cyano or a group which may be converted to a cyano group, the dotted line represents a double or a single bond and Z is a dimethylaminomethyl group or a group which may be converted to a dimethylaminomethyl group and Hal is a halogen, or  
       (ii) preparing the R-enantiomer of an acylated diol having the formula (IVr)  
       
         
           
           
               
               
           
         
       
       or a salt thereof;  
       wherein R, Z, the dotted line Hal are as defined above, W is O or S, and R 3  is —Y—R 1 , wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino; and Y is a bond, O, S or NH,  
       wherein the diol of formula (IIr) and/or the acylated diol of formula (IVr) is prepared by a method comprising:  
       (a) subjecting a racemic diol of formula (II)  
       
         
           
           
               
               
           
         
       
       wherein R is cyano or a group which may be converted to a cyano group, Z is —CH 2 —N(R′R″) wherein R′ and R″ are C 1-6 -alkyl, or R′ and R″ are connected to each other to form a cyclic structure including the N-atom to which they are attached, or Z is a group which may be converted to a dimethylaminomethyl group, the dotted line is a double or single bond, and Hal is a halogen;  
       to selective enzymatic acylation using an acylating agent having the formula  
       
         
           
           
               
               
           
         
       
       or an isocyanate having the formula R 1 —N═C═O or an isothiocyanate having the formula R 1 —N═C═S; wherein X is O or S; W is O or S; U is O or S; and V is halogen; provided that each of W and U is not S when X is S;  
       R 0  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl) amino, aryl, aryloxy, arylthio and heteroaryl, or R 0  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl) amino;  
       R 1  is as defined above for R 0 ; or R 0  and R 1  together form a chain of 3 to 5 carbon atoms;  
       R 2  is as defined above for R 0 , or R 2  is a suitable leaving group;  
       to form a mixture of the S- or R-enantiomer of a diol of formula (II) and the opposite enantiomer of a compound of formula (IV)  
       
         
           
           
               
               
           
         
       
       wherein R, Hal, the dotted line and Z are as defined above;  
       wherein W is O or S, and R 3  is —Y—R 1  wherein R 1  is C 1-10 -alkyl, C 2-10 -alkenyl or C 2-10 -alkynyl, all of which may optionally be substituted one or more times with substituents selected from C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino, di-(C 1-10 -alkyl)amino, aryl, aryloxy, arylthio and heteroaryl, or R 1  is aryl, wherein of the aryl and heteroaryl groups may optionally be substituted one or more times with substituents selected from C 1-10 -alkyl, C 2-10 -alkenyl, C 2-10 -alkynyl, C 1-10 -alkoxy, C 1-10 -alkylthio, hydroxy, halogen, amino, nitro, cyano, C 1-10 -alkylamino and di-(C 1-10 -alkyl)amino and Y is a bond, O, S or NH; or  
       (b) subjecting a racemic compound of formula (IV)  
       
         
           
           
               
               
           
         
       
       wherein R, Z, W, Hal, the dotted line and R 3  are as defined above; to selective enzymatic deacylation to form a mixture of the S- or R-enantiomer of a diol of formula (II)  
       
         
           
           
               
               
           
         
       
       wherein R, Hal, the dotted line and Z are as defined above, and the opposite enantiomer of a compound of formula (IV); and  
       (c) isolating, in either order, the S- or R-enantiomer of the compound of formula (II) or a salt thereof and/or the opposite enantiomer of the compound of formula (IV) or a salt thereof;  
       (iii) optionally subjecting the diol of formula (IIr) or the acylated diol of formula (IVr) to one or more reactions, in any order, selected from  
       (a) conversion of the group R to a cyano group,  
       (b) reduction of a double bond represented by the dotted line to a single bond,  
       (c) conversion of the group Z to a dimethylaminomethyl group, and/or  
       (d) conversion of the group Hal to a fluoro group;  
       (iv) effecting ring closure under acidic conditions of the diol of formula (IIr) or the acylated diol of formula (IVr), to form a mixture of the S-enantiomer of the compound of formula (V)  
       
         
           
           
               
               
           
         
       
       and a minor amount of the corresponding R-enantiomer;  
       (v) subjecting the compound of formula (V) to, in any order:  
       (a) conversion of the group R to a cyano group, if R is not cyano,  
       b) conversion of the group Z to a dimethylaminomethyl group, if Z is not dimethylaminomethyl,  
       (c) if the dotted line represents a double bond reduction to form a single bond, if the dotted line represents a double bond, and  
       (d) conversion of Hal to a fluoro group, if Hal is not fluoro; and  
       (vi) isolating escitalopram and/or racemic citalopram or a pharmaceutically acceptable salt thereof.  
     
   
   
       96 . The method of  claim 95  wherein the racemic citalopram is isolated by precipitating racemic citalopram free base or a salt thereof, and recovering escitalopram from the mother liquor of the precipitation.  
   
   
       97 . The method of  claim 95  wherein the mixture of the R- or S-enantiomer of the diol of formula (II) and the opposite enantiomer of the compound of formula (IV) are separated from each other by a process comprising 
 (a) treating the mixture with an acid in a mixture of water and an organic solvent;    (b) separating the aqueous phase containing the diol of formula (II) as a salt of said acid from the organic phase to obtain an organic phase containing the compound of formula (IV) as a salt of said acid;    (c) optionally isolating the diol of formula (II) as the base or a salt thereof; and    (d) optionally isolating the compound of formula (IV) as the base or a salt thereof.    
   
   
       98 . The method of  claim 95  wherein the R- or S-enantiomer of a the diol of formula (II) and the opposite enantiomer of the compound of formula (IV) are separated from each other by a process comprising 
 a) treating the mixture with a mixture of water, a protic organic solvent and an apolar organic solvent;    b) separating the aqueous phase containing the diol of formula (II), from the organic phase to obtain an organic phase containing the compound of formula (IV);    c) optionally isolating the diol of formula (II) from the aqueous phase and/or the compound of formula (IV) from the organic phase; and    d) optionally converting the diol of formula (II) and/or the compound of formula (IV) to a salt thereof.    
   
   
       99 . The method of  claim 8 , wherein R is cyano.  
   
   
       100 . The method of  claim 19 , wherein R 2  is a leaving group selected from succinimidyl, HOBt, and pfp.  
   
   
       101 . The method of  claim 25 , wherein R 0  and R 1  are each independently selected from methyl, ethyl, and propyl.  
   
   
       102 . The method of  claim 101 , wherein R 0  and R 1  are each independently propyl.  
   
   
       103 . The method of  claim 26 , wherein R 2  is a leaving group selected from succinimidyl, HOBt, and pfp.  
   
   
       104 . The method of  claim 35 , wherein R 1  is C 1-3 -alkyl.  
   
   
       105 . The method of  claim 104 , wherein R 1  is methyl, ethyl or propyl.  
   
   
       106 . The method of  claim 105 , wherein R 1  is propyl.  
   
   
       107 . The method of  claim 42 , wherein R 1  is propyl.  
   
   
       108 . The enantiomer of  claim 70  wherein R is cyano.  
   
   
       109 . The enantiomer of  claim 72  wherein Z is dimethylaminomethyl.  
   
   
       110 . The enantiomer of  claim 83  wherein R 1  is unbranched C 1-10 -alkyl.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.